References
Makarowski W, Zhao WW, Bevirt T, et al. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 2002 Apr; 10(4): 290–6
Karim A, Laurent A, Slater ME, et al. A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects. J Clin Pharmacol 2001 Oct; 41(10): 1111–9
Desjardins PJ, Grossman EH, Kuss ME, et al. The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively. Anesth Analg 2001 Sep; 93(3): 721–7
Jain KK. Evaluation of intravenous parecoxib for the relief of acute post-surgical pain. Expert Opin Investig Drugs 2000 Nov; 9(11): 2717–23
Harris SI, Kuss M, Hubbard RC, et al. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo. Clin Ther 2001 Sep; 23(9): 1422–8
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Warner, T. Valdecoxib. Drugs 62, 2072–2073 (2002). https://doi.org/10.2165/00003495-200262140-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200262140-00007